Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

This study aims to evaluate the efficacy and safety of the TPC regimen (nab-paclitaxel, cisplatin, and capecitabine) combined with apatinib and camrelizumab versus the GP regimen (gemcitabine and cisplatin) combined with camrelizumab for the treatment of high-risk regionally advanced nasopharyngeal carcinoma with a high risk of distant metastasis. The evaluation will be conducted through a prospective, controlled, open-label, multicenter phase 3 clinical trial in areas with high incidence of nasopharyngeal carcinoma.

Trial Details

NCT ID
NCT06438627
Phase
PHASE3
Sponsor
XIANG YANQUN
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • TPC combined with Apatinib and Camrelizumab
  • GP Combined With Camrelizumab
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Pathologically confirmed WHO type II or III;
  • Staging TanyN3M0 (UICC/AJCC 8th edition);
  • Treatment-naive patients with no history of other malignancies;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →